Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The association of cisplatin plus cyclophosphamide (PC) is considered to be the standard medical treatment for advanced ovarian carcinoma, while the role of doxorubicin in combination with cisplatin and cyclophosphamide (PAC regimen) is still controversial. Recently, four randomized clinical trials evaluating PC versus PAC regimen have been published. None of these studies showed a convincing advantage for the addition of doxorubicin to PC. By pooling the data from the 1200 or so patients included in these four studies and analyzing them with the statistical technique of metanalysis, a statistical benefit for PAC over PC is demonstrated in terms of pathologic complete response rate (30 vs 23%, P = 0.01) and 6-year survival rate (27 vs 21%, P = 0.01).

Original languageEnglish
Pages (from-to)152-155
Number of pages4
JournalBulletin du Cancer
Volume80
Issue number2
Publication statusPublished - 1993

Fingerprint

Anthracyclines
Combination Drug Therapy
Cyclophosphamide
Carcinoma
Doxorubicin
Cisplatin
Meta-Analysis
Survival Rate
Randomized Controlled Trials

Keywords

  • Anthracyclines
  • Meta-analysis
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. / Conte, P. F.

In: Bulletin du Cancer, Vol. 80, No. 2, 1993, p. 152-155.

Research output: Contribution to journalArticle

@article{86fd857337394e499a9866ffa0093600,
title = "Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma",
abstract = "The association of cisplatin plus cyclophosphamide (PC) is considered to be the standard medical treatment for advanced ovarian carcinoma, while the role of doxorubicin in combination with cisplatin and cyclophosphamide (PAC regimen) is still controversial. Recently, four randomized clinical trials evaluating PC versus PAC regimen have been published. None of these studies showed a convincing advantage for the addition of doxorubicin to PC. By pooling the data from the 1200 or so patients included in these four studies and analyzing them with the statistical technique of metanalysis, a statistical benefit for PAC over PC is demonstrated in terms of pathologic complete response rate (30 vs 23{\%}, P = 0.01) and 6-year survival rate (27 vs 21{\%}, P = 0.01).",
keywords = "Anthracyclines, Meta-analysis, Ovarian carcinoma",
author = "Conte, {P. F.}",
year = "1993",
language = "English",
volume = "80",
pages = "152--155",
journal = "Bulletin du Cancer",
issn = "0007-4551",
publisher = "John Libbey Eurotext",
number = "2",

}

TY - JOUR

T1 - Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma

AU - Conte, P. F.

PY - 1993

Y1 - 1993

N2 - The association of cisplatin plus cyclophosphamide (PC) is considered to be the standard medical treatment for advanced ovarian carcinoma, while the role of doxorubicin in combination with cisplatin and cyclophosphamide (PAC regimen) is still controversial. Recently, four randomized clinical trials evaluating PC versus PAC regimen have been published. None of these studies showed a convincing advantage for the addition of doxorubicin to PC. By pooling the data from the 1200 or so patients included in these four studies and analyzing them with the statistical technique of metanalysis, a statistical benefit for PAC over PC is demonstrated in terms of pathologic complete response rate (30 vs 23%, P = 0.01) and 6-year survival rate (27 vs 21%, P = 0.01).

AB - The association of cisplatin plus cyclophosphamide (PC) is considered to be the standard medical treatment for advanced ovarian carcinoma, while the role of doxorubicin in combination with cisplatin and cyclophosphamide (PAC regimen) is still controversial. Recently, four randomized clinical trials evaluating PC versus PAC regimen have been published. None of these studies showed a convincing advantage for the addition of doxorubicin to PC. By pooling the data from the 1200 or so patients included in these four studies and analyzing them with the statistical technique of metanalysis, a statistical benefit for PAC over PC is demonstrated in terms of pathologic complete response rate (30 vs 23%, P = 0.01) and 6-year survival rate (27 vs 21%, P = 0.01).

KW - Anthracyclines

KW - Meta-analysis

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027408089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027408089&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 152

EP - 155

JO - Bulletin du Cancer

JF - Bulletin du Cancer

SN - 0007-4551

IS - 2

ER -